Brief: Transgene Says Preclinical Results Showing TG6050 Induces Tumor Regression

Transgene SA

17/04/2023 06:40

April 17 (Reuters) - Transgene SA  TRNG.PA :
    * PRESENTATION AT AACR PRECLINICAL RESULTS SHOWING THAT
TG6050
INDUCES TUMOR REGRESSION  THROUGH THE ACTIVATION OF INNATE AND
ADAPTIVE IMMUNE RESPONSES
    * THE PHASE I DELIVIR TRIAL WAS INITIATED IN 2023 AND IS
CURRENTLY
ENROLLING PATIENTS
    * MTG6050 TREATMENT INCREASED T CELL RESPONSES CAPABLE OF
KILLING
CANCER CELLS
    * IN SEVERAL MICE MODELS, MTG6050 DISPLAYED A VERY STRONG
ANTI-TUMOR ACTIVITY
    * THESE OUTSTANDING PRE-CLINICAL FINDINGS CLEARLY SUPPORT
CLINICAL
DEVELOPMENT OF TG6050, WHICH HAS RECENTLY STARTED PHASE I
DELIVIR TRIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER - CEO

Source text for Eikon:  ID:nBw6QhqNca 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))